BDTX Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -- compared to Black Diamond Therapeutics's net margin of -49.65%. Black Diamond Therapeutics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Black Diamond Therapeutics has a consensus price target of --, signalling upside risk potential of 562.1%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 546.03%. Given that Black Diamond Therapeutics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Black Diamond Therapeutics is more attractive than NovaBay Pharmaceuticals.

Black Diamond Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

Black Diamond Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Black Diamond Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Black Diamond Therapeutics quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Black Diamond Therapeutics's net income of -$15.6M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Black Diamond Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Black Diamond Therapeutics is -- versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Black Diamond Therapeutics's net margin of -2357.27%. Black Diamond Therapeutics's return on equity of -- beat Palatin Technologies's return on equity of --.

Black Diamond Therapeutics has a consensus price target of --, signalling upside risk potential of 562.1%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1431.53%. Given that Palatin Technologies has higher upside potential than Black Diamond Therapeutics, analysts believe Palatin Technologies is more attractive than Black Diamond Therapeutics.

Black Diamond Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.

Black Diamond Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Black Diamond Therapeutics pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Black Diamond Therapeutics quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. Black Diamond Therapeutics's net income of -$15.6M is lower than Palatin Technologies's net income of -$7.8M. Notably, Black Diamond Therapeutics's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Black Diamond Therapeutics is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -- compared to Black Diamond Therapeutics's net margin of --. Black Diamond Therapeutics's return on equity of -- beat Theriva Biologics's return on equity of --.

Black Diamond Therapeutics has a consensus price target of --, signalling upside risk potential of 562.1%. On the other hand Theriva Biologics has an analysts' consensus of $100.00 which suggests that it could grow by 6056.46%. Given that Theriva Biologics has higher upside potential than Black Diamond Therapeutics, analysts believe Theriva Biologics is more attractive than Black Diamond Therapeutics.

Black Diamond Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.329, suggesting its more volatile than the S&P 500 by 32.874%.

Black Diamond Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Black Diamond Therapeutics pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Black Diamond Therapeutics quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Black Diamond Therapeutics's net income of -$15.6M is lower than Theriva Biologics's net income of -$7.7M. Notably, Black Diamond Therapeutics's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Black Diamond Therapeutics is -- versus 0.90x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

Vanda Pharmaceuticals has a net margin of -- compared to Black Diamond Therapeutics's net margin of -11.17%. Black Diamond Therapeutics's return on equity of -- beat Vanda Pharmaceuticals's return on equity of -3.02%.

Black Diamond Therapeutics has a consensus price target of --, signalling upside risk potential of 562.1%. On the other hand Vanda Pharmaceuticals has an analysts' consensus of $12.17 which suggests that it could grow by 152.95%. Given that Black Diamond Therapeutics has higher upside potential than Vanda Pharmaceuticals, analysts believe Black Diamond Therapeutics is more attractive than Vanda Pharmaceuticals.

Black Diamond Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Vanda Pharmaceuticals has a beta of 0.757, suggesting its less volatile than the S&P 500 by 24.283%.

Black Diamond Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Black Diamond Therapeutics pays -- of its earnings as a dividend. Vanda Pharmaceuticals pays out -- of its earnings as a dividend.

Black Diamond Therapeutics quarterly revenues are --, which are smaller than Vanda Pharmaceuticals quarterly revenues of $47.7M. Black Diamond Therapeutics's net income of -$15.6M is lower than Vanda Pharmaceuticals's net income of -$5.3M. Notably, Black Diamond Therapeutics's price-to-earnings ratio is -- while Vanda Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Black Diamond Therapeutics is -- versus 1.46x for Vanda Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.